IL-CHEETAH-DIGITAL
Cheetah Digital , a cross-channel customer engagement solution provider for the modern marketer, today announces Cheetah Personalization at Signals 2020 . This next-generation personalization solution is the newest addition to the Cheetah Customer Engagement Suite that includes the Cheetah Engagement Data Platform, Experiences, Messaging, and Loyalty. Cheetah Personalization helps marketers orchestrate real-time interactions across all channels and touchpoints.
To remain competitive in today’s signal-saturated world, marketers need to deliver relevant, personalized content throughout the customer journey. Ninety-one percent of consumers are more likely to shop with brands who recognize, remember, and provide relevant offers and recommendations. Furthermore, real-time offers and content can be 10 times more effective than traditional outbound marketing campaigns.
“Personalization is in the fabric of everything marketers do. But as a strategy, technology and a market, personalization is ripe for reinvention,” said Sameer Kazi, CEO at Cheetah Digital. “We wanted to create a technology blueprint for brands to achieve personalization success. With Cheetah Digital, the next-generation of personalization is here. It’s the way forward for marketers to achieve their personalization, and ultimately business, goals.”
Organizations need technology to orchestrate each aspect of personalization, from data to distribution, in order to unlock the full power of personalization. With cookies and third-party data no longer being viable options for marketers, first and zero-party data are at the core of next-generation personalization.
Cheetah Personalization leverages analytics and machine learning to evaluate every customer on an individual level to derive the right content, offer, channel and sequence for a customer journey. The new solution includes delivering the next-best experience, next-best journey and next-best offers. These capabilities are enabled by three key product offerings:
- Cheetah Real-Time Personalization: Allows you to engage with customers in real-time with targeted experiences by capturing streaming data on web and mobile.
- Cheetah Journey Designer: Gives marketers the power to build, manage and optimize multi-step, multi-stage customer journeys at scale.
- Cheetah Intelligent Offers : Applies marketing insights and machine learning to optimize experiences and generate the next best offer and next best action.
“Personalization is one of the most critical themes for our customers and organization,” said Bill Ingram, Chief Product Officer at Cheetah Digital. “It’s not about guesswork, cookies or third-party data. The next generation of personalization is about providing a value exchange for consumers in the “moment” when you have them on your mobile app, on your site, in your store, where you can provide them something that will generate trust and affinity with the brand. With the data foundation of the Engagement Data Platform, we are well equipped to deliver a first class, next-generation personalization solution.”
“We were tasked with making better use of our data for more effective personalization for our guests in the face of a rapidly changing landscape,” said Katie Rhine, Corporate Marketing Manager at SeaWorld. “With Cheetah Digital’s solution, we were able to leverage zero-party data from email and deliver a more relevant and personalized experience for our guests. Now, we can personalize experiences at scale and create loyal customers across all our locations.”
This follows Cheetah Digital’s recent recognition in the MarTech Breakthrough Awards, where it was named Best Enterprise CRM Solution . To learn more about these updates and the new Cheetah Personalization solution, visit cheetahdigital.com/solutions/cheetah-personalization .
About Cheetah Digital
Cheetah Digital is a cross-channel customer engagement solution provider for the modern marketer. The Cheetah Digital Customer Engagement Suite enables marketers to create personalized experiences, cross-channel messaging, and loyalty strategies, underpinned by an engagement data platform that can scale to meet the changing demands of today's consumer. Many of the world’s best brands, including Hilton, Neiman Marcus, Walgreens, and Williams-Sonoma trust Cheetah Digital to help them drive revenue, build lasting customer relationships, and deliver a unique value exchange throughout the customer lifecycle. To learn more, visit www.cheetahdigital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005797/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
